COVID-19 - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “COVID-19 - Pipeline Insight, 2021,” report provides comprehensive insights about 150+ companies and 200+ pipeline drugs in COVID-19 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
COVID-19: Overview
Coronavirus disease (COVID-19) is an infectious disease caused by the most recently discovered corona virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease causes respiratory illness (like the flu) with symptoms such as a cough, fever, and difficulty breathing. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Elderly people and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness. The COVID-19 virus is primarily transmitted through droplets of saliva or discharge from the nose when an infected person coughs or sneezes. People can catch COVID-19 if they breathe in droplets from a person with COVID-19 who coughs out or exhales droplets. It also spreads when a person touches a surface or objects that has the virus on it, and then touches their eyes, nose, or mouth.
Rapid and accurate detection of COVID-19 is crucial to control outbreaks in the community and in hospitals. Current diagnostic tests for coronavirus include reverse-transcription polymerase chain reaction (RT-PCR), real?time RT-PCR (rRT?PCR), and reverse transcription loop?mediated isothermal amplification (RT?LAMP). RT-LAMP has similar sensitivity to rRT-PCR, is highly specific and is used to detect MERS-CoV. COVID-19 is a new disease and there is limited information regarding risk factors for severe illness. Based on currently available information and clinical expertise, people of all ages can be infected by the novel coronavirus. Older people, and people with pre-existing medical conditions (such as asthma, diabetes, and heart disease) appear to be more vulnerable to becoming severely ill with the virus.
Report Highlights
This segment of the COVID-19 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
COVID-19 Emerging Drugs
It is being developed by Vir Biotechnology in collaboration with GlaxoSmithKline. In May, 2021, The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has issued a positive scientific opinion for GlaxoSmithKline (GSK) and Vir Biotechnology’s sotrovimab (VIR-7831) as early Covid-19 treatment.
Further product details are provided in the repor
COVID-19: Therapeutic Assessment
This segment of the report provides insights about the different COVID-19 drugs segregated based on following parameters that define the scope of the report, such as:
COVID-19: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses COVID-19 therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging COVID-19 drugs.
COVID-19 Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “COVID-19 - Pipeline Insight, 2021,” report provides comprehensive insights about 150+ companies and 200+ pipeline drugs in COVID-19 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
COVID-19: Overview
Coronavirus disease (COVID-19) is an infectious disease caused by the most recently discovered corona virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease causes respiratory illness (like the flu) with symptoms such as a cough, fever, and difficulty breathing. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Elderly people and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness. The COVID-19 virus is primarily transmitted through droplets of saliva or discharge from the nose when an infected person coughs or sneezes. People can catch COVID-19 if they breathe in droplets from a person with COVID-19 who coughs out or exhales droplets. It also spreads when a person touches a surface or objects that has the virus on it, and then touches their eyes, nose, or mouth.
Rapid and accurate detection of COVID-19 is crucial to control outbreaks in the community and in hospitals. Current diagnostic tests for coronavirus include reverse-transcription polymerase chain reaction (RT-PCR), real?time RT-PCR (rRT?PCR), and reverse transcription loop?mediated isothermal amplification (RT?LAMP). RT-LAMP has similar sensitivity to rRT-PCR, is highly specific and is used to detect MERS-CoV. COVID-19 is a new disease and there is limited information regarding risk factors for severe illness. Based on currently available information and clinical expertise, people of all ages can be infected by the novel coronavirus. Older people, and people with pre-existing medical conditions (such as asthma, diabetes, and heart disease) appear to be more vulnerable to becoming severely ill with the virus.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence COVID-19 R&D. The therapies under development are focused on novel approaches for COVID-19.
This segment of the COVID-19 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
COVID-19 Emerging Drugs
- Sotrovimab: Vir Biotechnology/ GlaxoSmithKline
It is being developed by Vir Biotechnology in collaboration with GlaxoSmithKline. In May, 2021, The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has issued a positive scientific opinion for GlaxoSmithKline (GSK) and Vir Biotechnology’s sotrovimab (VIR-7831) as early Covid-19 treatment.
- VERU111: Veru Inc.
Further product details are provided in the repor
COVID-19: Therapeutic Assessment
This segment of the report provides insights about the different COVID-19 drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on COVID-19
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
COVID-19: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses COVID-19 therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging COVID-19 drugs.
COVID-19 Report Insights
- COVID-19 Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing COVID-19 drugs?
- How many COVID-19 drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for COVID-19?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the COVID-19 therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for COVID-19 and their status?
- What are the key designations that have been granted to the emerging drugs?
- Vir Biotechnology/ GlaxoSmithKline
- Can-Fite Biopharma
- AbbVie
- Novartis
- Tonix Pharmaceuticals
- Molecular Partners
- Veru Inc.
- PTC Therapeutics
- RedHill Biopharma
- SAb Biotherapeutics
- Adagio Therapeutics
- Valneva
- Novavax
- Inovio Pharmaceuticals
- VBI Vaccines
- Rigel Pharmaceuticals
- Translate Bio
- Evelo Biosciences
- Cocrystal Pharma
- Icosavax
- Atea Pharmaceuticals
- NovaLead
- Sotrovimab
- CF-101
- ABBV-47D11
- MAS-825
- TNX 1800
- MP-0420
- MP0423
- VERU-111
- PTC-299
- RHB-107
- SAB-185
- ADG20
- VLA2001
- NVX-CoV2373
- INO-4800
- VBI-2902
- Fostamatinib
- MRT5500
- EDP-1815
- CDI-45205
- IVX-411
- AT?527
- NLP21
Introduction
Executive Summary
COVID-19: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
COVID-19– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
COVID-19 companies’ collaborations, Licensing, Acquisition -Deal Value Trends
COVID-19 Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
VERU-111: Veru Inc.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
CF-101: Can-Fite Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ABBV-47D11: AbbVie
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
TNX-1800: Tonix Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
COVID-19 Key Companies
COVID-19 Key Products
COVID-19- Unmet Needs
COVID-19- Market Drivers and Barriers
COVID-19- Future Perspectives and Conclusion
COVID-19 Analyst Views
COVID-19 Key Companies
Appendix
Executive Summary
COVID-19: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
COVID-19– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
COVID-19 companies’ collaborations, Licensing, Acquisition -Deal Value Trends
COVID-19 Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
VERU-111: Veru Inc.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
CF-101: Can-Fite Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ABBV-47D11: AbbVie
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
TNX-1800: Tonix Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
COVID-19 Key Companies
COVID-19 Key Products
COVID-19- Unmet Needs
COVID-19- Market Drivers and Barriers
COVID-19- Future Perspectives and Conclusion
COVID-19 Analyst Views
COVID-19 Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for COVID-19
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for COVID-19
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for COVID-19
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for COVID-19
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
